The Pharmacy Times® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) agreed on a positive opinion for AbbVie’s upadacitinib (RINVOQ), according to the company.
Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).
Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.
Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis.
A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.
The higher dose is only approved for patients with ulcerative colitis, and not for RA.
The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.
Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.
New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a â€œtreat-to-targetâ€ goal for low disease activity.